Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 14/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4967696 | 0.87 | F2 (0.48) | CNR2F2KCNH2CNR1PTGDR2 | |
| SCHEMBL4965783 | 0.85 | F2 (0.46) | CNR2F2KCNH2CNR1 | |
| SCHEMBL4966204 | 0.80 | CNR2 (0.71) | CNR2KCNH2CNR1 | |
| SCHEMBL4968385 | 0.80 | CNR2 (0.68) | CNR2KCNH2CNR1 | |
| SCHEMBL4966127 | 0.79 | CNR2 (0.72) | CNR2KCNH2CNR1 | |
| SCHEMBL4966137 | 0.77 | CNR2 (0.68) | CNR2KCNH2CNR1 | |
| SCHEMBL4966450 | 0.77 | CNR2 (0.62) | CNR2F2KCNH2CNR1 | |
| SCHEMBL4966435 | 0.76 | CNR2 (0.62) | CNR2KCNH2CNR1 | |
| SCHEMBL14074475 | 0.75 | CNR2 (0.64) | CNR2KCNH2CNR1 | |
| SCHEMBL4966183 | 0.75 | CNR2 (0.64) | CNR2KCNH2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221178-A1 | Benzimidazole Derivatives,Compositions Containing Them, Preparation Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221178-A1 | Benzimidazole Derivatives,Compositions Containing Them, Preparation Thereof and Uses Thereof | TBXA2R, CYP2C19, CYP3A43 | CNR2 292/4885F2 1296/4885KCNH2 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.